Products

API Powder Simvastatin CAS 79902-63-9 //Proglumide CAS 6620-60-6//Lycorine Hydrochloride CAS 2188-68-3 // Epalrestat CAS 82159-09-9 //CAS 179324 -69-7 Bortezomib

China API Powder Simvastatin CAS 79902-63-9 //Proglumide CAS 6620-60-6//Lycorine Hydrochloride CAS 2188-68-3 // Epalrestat CAS 82159-09-9 //CAS 179324-69-7 Bortezomib, Find details about China Simvastatin, CAS 79902-63-9 from API Powder Simvastatin CAS 79902-63-9 //Proglumide CAS 6620-60-6//Lycorine Hydrochloride CAS 2188-68-3 // Epalrestat CAS 82159-09-9 //CAS 179324-69-7 Bortezomib

Model NO.
Bortezomib
Mf
C19h25bn4o4
MW
384.24
CAS
179324-69-7
Appearance
White Crystalline Powder
Function
Biological and Pharmaceutical Intermediates
Shelf Life
2 Years
Test Method
HPLC UV
Storage
Cool Dry Place
Payment
Tt.Western Union .Credit Card.Moneygram
Delivery Time
Within 2 Days
Certificate
COA MSDS
Sample
Available
Trademark
Faithful
Transport Package
Aluminum Foil Bag Packaging
Specification
10g/bag; 100g/bag; 1kg/bag
Origin
China
Model NO.
Bortezomib
Mf
C19h25bn4o4
MW
384.24
CAS
179324-69-7
Appearance
White Crystalline Powder
Function
Biological and Pharmaceutical Intermediates
Shelf Life
2 Years
Test Method
HPLC UV
Storage
Cool Dry Place
Payment
Tt.Western Union .Credit Card.Moneygram
Delivery Time
Within 2 Days
Certificate
COA MSDS
Sample
Available
Trademark
Faithful
Transport Package
Aluminum Foil Bag Packaging
Specification
10g/bag; 100g/bag; 1kg/bag
Origin
China
API Powder Simvastatin CAS 79902-63-9 //Proglumide CAS 6620-60-6//Lycorine Hydrochloride CAS 2188-68-3 // Epalrestat CAS 82159-09-9 //CAS 179324-69-7 BortezomibAPI powder Simvastatin CAS 79902-63-9 //proglumide CAS 6620-60-6//lycorine hydrochloride CAS 2188-68-3 // epalrestat CAS 82159-09-9 //CAS 179324-69-7 Bortezomib

Introduction
Bortezomib is the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S,proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. Targets the ubiquitin
proteasome pathway.

Function

Bortezomib Is the first therapeutic proteasome inhibitor to be tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. 

In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing disease.

 

Specification
 

ItemSpecification
Assay>98%
AppearanceWhite powder
OdorCharacteristic
TasteCharacteristic
Particle SizeNLT 100% Through 80 mesh
Loss on Drying<2.0%
Heavy metals≤10ppm
Arsenic≤3ppm
Lead≤3ppm
<2.0%
Total Plate Count≤1000cfu/g
Total Yeast & Mold≤100cfu/g
E.ColiNegative
SalmonellaNegative
API Powder Simvastatin CAS 79902-63-9 //Proglumide CAS 6620-60-6//Lycorine Hydrochloride CAS 2188-68-3 // Epalrestat CAS 82159-09-9 //CAS 179324-69-7 BortezomibAPI Powder Simvastatin CAS 79902-63-9 //Proglumide CAS 6620-60-6//Lycorine Hydrochloride CAS 2188-68-3 // Epalrestat CAS 82159-09-9 //CAS 179324-69-7 BortezomibAPI Powder Simvastatin CAS 79902-63-9 //Proglumide CAS 6620-60-6//Lycorine Hydrochloride CAS 2188-68-3 // Epalrestat CAS 82159-09-9 //CAS 179324-69-7 BortezomibAPI Powder Simvastatin CAS 79902-63-9 //Proglumide CAS 6620-60-6//Lycorine Hydrochloride CAS 2188-68-3 // Epalrestat CAS 82159-09-9 //CAS 179324-69-7 BortezomibAPI Powder Simvastatin CAS 79902-63-9 //Proglumide CAS 6620-60-6//Lycorine Hydrochloride CAS 2188-68-3 // Epalrestat CAS 82159-09-9 //CAS 179324-69-7 BortezomibAPI Powder Simvastatin CAS 79902-63-9 //Proglumide CAS 6620-60-6//Lycorine Hydrochloride CAS 2188-68-3 // Epalrestat CAS 82159-09-9 //CAS 179324-69-7 BortezomibAPI Powder Simvastatin CAS 79902-63-9 //Proglumide CAS 6620-60-6//Lycorine Hydrochloride CAS 2188-68-3 // Epalrestat CAS 82159-09-9 //CAS 179324-69-7 Bortezomib

You Might Also Like